tetano
Editor, Senior Moderator
Am J Ophthalmol
. 2022 May 21;S0002-9394(22)00211-2.
doi: 10.1016/j.ajo.2022.05.013. Online ahead of print.
COVID-19 vaccination hesitancy and its association with altered presentation of primary rhegmatogenous retinal detachment
Rusdeep Mundae[SUP] 1 [/SUP], Sushant Wagley[SUP] 2 [/SUP], Edwin H Ryan[SUP] 3 [/SUP], D Wilkin Parke[SUP] 3 [/SUP], Robert A Mittra[SUP] 2 [/SUP], Peter H Tang[SUP] 4 [/SUP]
Affiliations
Abstract
Purpose: Evaluate factors associated with coronavirus 2019 (COVID-19) vaccine hesitancy and clinical trends in primary rhegmatogenous retinal detachments (RRD) during first year of vaccine availability.
Design: Single-center, clinical cohort study METHODS: : Consecutive patients from December 14, 2020 to December 12, 2021 presenting vaccinated (Prior-), subsequently vaccinated (Later-), or remaining unvaccinated (Never-Vax). Primary outcome was proportion with macula-off (mac-off) RRD. Secondary outcomes included logarithm of the minimum angle of resolution (logMAR) best-corrected visual acuity (BCVA), primary proliferative vitreoretinopathy (PVR), proportion lost to follow-up, and distance traveled.
Results: 1,047 patients were divided into 391 Prior-, 252 Later-, and 404 Never-Vax cohorts. Significantly greater proportion of Later- and Never-Vax cohorts presented with mac-off RRDs (Prior-Vax = 44.5%; Later-Vax = 54%, P < 0.0001; Never-Vax = 57.9%, P < 0.0001) and primary PVR (Prior-Vax = 4.3%; Later-Vax = 13.6%, P < 0.0001; Never-Vax = 17.1%, P < 0.0001) compared to Prior-Vax cohort. Significantly greater proportion of Never-Vax cohort (7.7%, P < 0.0001) were lost to follow-up compared to Prior- (2.3%) and Later-Vax (2.2%) cohorts. Never-Vax cohort (median = 35 miles) traveled further compared to Prior- (median = 22.3 miles; P < 0.0001) and Later-Vax cohorts (25.45 miles; P = 0.0038). Prior-Vax cohort had significantly better (P < 0.05) initial (median = 0.30 logMAR) and final (0.18 logMAR) BCVA compared to Later- (Initial: 0.54 logMAR; Final: 0.30 logMAR) and Never-vax (Initial: 0.70 logMAR; Final: 0.40 logMAR) cohorts.
Conclusions: COVID-19 vaccine hesitancy is associated with worse clinical presentation and outcomes for primary RRD.
Keywords: COVID-19; PVR; RD; Rhegmatogenous; hesitancy; pandemic; proliferative vitreoretinopathy; retina; retinal detachment; subretinal fluid; vaccination; vaccine; vaccine hesitancy.
. 2022 May 21;S0002-9394(22)00211-2.
doi: 10.1016/j.ajo.2022.05.013. Online ahead of print.
COVID-19 vaccination hesitancy and its association with altered presentation of primary rhegmatogenous retinal detachment
Rusdeep Mundae[SUP] 1 [/SUP], Sushant Wagley[SUP] 2 [/SUP], Edwin H Ryan[SUP] 3 [/SUP], D Wilkin Parke[SUP] 3 [/SUP], Robert A Mittra[SUP] 2 [/SUP], Peter H Tang[SUP] 4 [/SUP]
Affiliations
- PMID: 35609676
- DOI: 10.1016/j.ajo.2022.05.013
Abstract
Purpose: Evaluate factors associated with coronavirus 2019 (COVID-19) vaccine hesitancy and clinical trends in primary rhegmatogenous retinal detachments (RRD) during first year of vaccine availability.
Design: Single-center, clinical cohort study METHODS: : Consecutive patients from December 14, 2020 to December 12, 2021 presenting vaccinated (Prior-), subsequently vaccinated (Later-), or remaining unvaccinated (Never-Vax). Primary outcome was proportion with macula-off (mac-off) RRD. Secondary outcomes included logarithm of the minimum angle of resolution (logMAR) best-corrected visual acuity (BCVA), primary proliferative vitreoretinopathy (PVR), proportion lost to follow-up, and distance traveled.
Results: 1,047 patients were divided into 391 Prior-, 252 Later-, and 404 Never-Vax cohorts. Significantly greater proportion of Later- and Never-Vax cohorts presented with mac-off RRDs (Prior-Vax = 44.5%; Later-Vax = 54%, P < 0.0001; Never-Vax = 57.9%, P < 0.0001) and primary PVR (Prior-Vax = 4.3%; Later-Vax = 13.6%, P < 0.0001; Never-Vax = 17.1%, P < 0.0001) compared to Prior-Vax cohort. Significantly greater proportion of Never-Vax cohort (7.7%, P < 0.0001) were lost to follow-up compared to Prior- (2.3%) and Later-Vax (2.2%) cohorts. Never-Vax cohort (median = 35 miles) traveled further compared to Prior- (median = 22.3 miles; P < 0.0001) and Later-Vax cohorts (25.45 miles; P = 0.0038). Prior-Vax cohort had significantly better (P < 0.05) initial (median = 0.30 logMAR) and final (0.18 logMAR) BCVA compared to Later- (Initial: 0.54 logMAR; Final: 0.30 logMAR) and Never-vax (Initial: 0.70 logMAR; Final: 0.40 logMAR) cohorts.
Conclusions: COVID-19 vaccine hesitancy is associated with worse clinical presentation and outcomes for primary RRD.
Keywords: COVID-19; PVR; RD; Rhegmatogenous; hesitancy; pandemic; proliferative vitreoretinopathy; retina; retinal detachment; subretinal fluid; vaccination; vaccine; vaccine hesitancy.